Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Pérez Bercoff, Lena ^a   Valentini, Davide ^a   Gaseitsiwe, Simani ^b   Mahdavifar, Shahnaz ^c   Schutkowski, Mike ^d   Poiret, Thomas ^e   Pérez Bercoff, Asa ^f   Ljungman, Per ^a   Maeurer, Markus J ^a,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Microbiology   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 2; PROTEOME; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; VIRUS PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; EXCLUSIVE RECOGNITION ANALYSIS; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOREACTIVITY; MICROARRAY ANALYSIS; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; WESTERN BLOTTING; B LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN MICROARRAY;

B-LYMPHOCYTES; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; PROTEIN ARRAY ANALYSIS; PROTEOME; VIRAL PROTEINS;

EID: 84899687849     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089648     Document Type: Article

References (61)

1. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, et al. (2006) Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91: 78-83. (Pubitemid 43235389)
2. Weseslindtner L, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, et al. (2012) Prospective Analysis of Human Cytomegalovirus DNAemia and Specific CD8+ T Cell Responses in Lung Transplant Recipients. Am J Transplant 12: 2172-2180.
3. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, et al. (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201: 1031-1036. (Pubitemid 40524670)
4. Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M (1998) Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 178: 1233-1243.
5. Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lonnqvist B, et al. (1997) No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplantation 19: 233-236. (Pubitemid 27077478)
6. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD (1991) Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant [see comments]. J Infect Dis 164: 483-487.
7. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, et al. (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirusspecific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 343-351. (Pubitemid 32677436)
8. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64: 1079-1085. (Pubitemid 20087744)
9. Furebring C, Speckner A, Mach M, Sandlie I, Norderhaug L, et al. (2002) Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region. Mol Immunol 38: 833-840. (Pubitemid 34260885)
10. Shimamura M, Mach M, Britt WJ (2006) Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80: 4591-4600.
11. Wahren B, Gahrton G, Linde A, Ljungman P, Lonnqvist B, et al. (1984) Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. Journal of Infectious Diseases 150: 358-365. (Pubitemid 14037020)
12. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, Aschan J, Brandt L, et al. (1994) Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 84: 657-663. (Pubitemid 24215971)
13. Ljungman P, Wiklund HM, Duraj V, Hammarström L, Lönnqvist B, et al. (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 162: 496-500. (Pubitemid 20239969)
14. Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, et al. (1990) Bcell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 76: 1647-1656. (Pubitemid 20364032)
15. Parkman R, Weinberg KI (1997) Immunological reconstitution following bone marrow transplantation. Immunol Rev 157: 73-78. (Pubitemid 27303122)
16. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360: 1191-1199.
17. Kuzmina Z, Greinix HT, Weigl R, Kormoczi U, Rottal A, et al. (2011) Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood 117: 2265-2274.
18. Chuang HY, Hofree M, Ideker T (2010) A decade of systems biology. Annu Rev Cell Dev Biol 26: 721-744.
19. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
20. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12: 786-795.
21. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, et al. (1994) A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83: 2723-2730. (Pubitemid 24135867)
22. Ringden O, Remberger M, Dahllof G, Garming-Legert K, Karlsson H, et al. (2011) Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. Eur J Haematol 87: 503-509.
23. Yun Z, Lewensohn-Fuchs I, Ljungman P, Ringholm L, Jonsson J, et al. (2003) A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods 110: 73-79. (Pubitemid 36579161)
24. Yun Z, Lewensohn-Fuchs I, Ljungman P, Vahlne A (2000) Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays. Transplantation 69: 1733-1736.
25. Gaseitsiwe S, Valentini D, Mahdavifar S, Magalhaes I, Hoft DF, et al. (2008) Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS One 3: e3840.
26. Nahtman T, Jernberg A, Mahdavifar S, Zerweck J, Schutkowski M, et al. (2007) Validation of peptide epitope microarray experiments and extraction of quality data. J Immunol Methods 328: 1-13. (Pubitemid 350007612)
27. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, et al. (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154: 125-169. (Pubitemid 20151030)
28. Murphy E, Rigoutsos I, Shibuya T, Shenk TE (2003) Reevaluation of human cytomegalovirus coding potential. Proc Natl Acad Sci U S A 100: 13585-13590. (Pubitemid 37444784)
29. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572. (Pubitemid 34526173)
30. Conesa A, Nueda MJ, Ferrer A, Talon M (2006) maSigPro: a method to identify significantly differential expression profiles in time-course microarray experiments. Bioinformatics 22: 1096-1102.
31. Knight R, Maxwell P, Birmingham A, Carnes J, Caporaso JG, et al. (2007) PyCogent: a toolkit for making sense from sequence. Genome Biol 8: R171.
32. Magalhaes I, Vudattu NK, Ahmed RK, Kuhlmann-Berenzon S, Ngo Y, et al. (2010) High content cellular immune profiling reveals differences between rhesus monkeys and men. Immunology 131: 128-140.
33. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O (2001) Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 15: 1976-1985. (Pubitemid 33115007)
34. Bronzini M, Luganini A, Dell'Oste V, De Andrea M, Landolfo S, et al. (2012) The US16 gene of human cytomegalovirus is required for efficient viral infection of endothelial and epithelial cells. J Virol 86: 6875-6888.
35. Vidal M, Cusick ME, Barabasi AL (2011) Interactome networks and human disease. Cell 144: 986-998.
36. Linnebacher M, Lorenz P, Koy C, Jahnke A, Born N, et al. (2012) Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples. Anal Bioanal Chem 403: 227-238.
37. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
38. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, et al. (2011) Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85: 11502-11519.
39. Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, et al. (2006) Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol 24: 391-418.
40. Prechl J, Papp K, Erdei A (2010) Antigen microarrays: descriptive chemistry or functional immunomics? Trends Immunol 31: 133-137.
41. Robinson WH, Steinman L, Utz PJ (2002) Protein and peptide array analysis of autoimmune disease. Biotechniques Suppl: 66-69. (Pubitemid 36008166)
42. Hecker M, Lorenz P, Steinbeck F, Hong L, Riemekasten G, et al. (2012) Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmun Rev 11: 180-190.
43. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, et al. (2012) Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148: 1293-1307.
44. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, et al. (2008) Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol 127: 14-25.
45. Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, Rossi R, Bistoni F, et al. (2002) Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem 48: 121-130. (Pubitemid 34038131)
46. Wahren B, Gahrton G, Linde A, Ljungman P, Lonnqvist B, et al. (1984) Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis 150: 358-365. (Pubitemid 14037020)
47. Wang GC, Dash P, McCullers JA, Doherty PC, Thomas PG (2012) T cell receptor alphabeta diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med 4: 128ra142.
48. Barrios Y, Knor S, Lantto J, Mach M, Ohlin M (2007) Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties. Mol Immunol 44: 680-690. (Pubitemid 44415022)
49. Lang D, Vornhagen R, Rothe M, Hinderer W, Sonneborn HH, et al. (2001) Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers. Clin Diagn Lab Immunol 8: 747-756. (Pubitemid 32613701)
50. Rhodes G, Smith RS, Rubin RE, Vaughan J, Horwitz CA (1990) Identical IgM antibodies recognizing a glycine-alanine epitope are induced during acute infection with Epstein-Barr virus and cytomegalovirus. J Clin Lab Anal 4: 456-464.
51. Tedeschi R, Bidoli E, Agren A, Hallmans G, Wadell G, et al. (2006) Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Vasterbotten County, Sweden. J Med Virol 78: 372-378. (Pubitemid 43327837)
52. Enbom M, Sheldon J, Lennette E, Schulz T, Ablashi DV, et al. (2000) Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study. J Med Virol 62: 498-504.
53. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77 (Pt 7): 1537-1547. (Pubitemid 26248669)
54. Cai JS, Jang HK, Izumiya Y, Tsushima Y, Kato K, et al. (1999) Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: comparison with glycoprotein M genes of Herpesviridae family. J Vet Med Sci 61: 503-511. (Pubitemid 129586524)
55. Burkhardt C, Himmelein S, Britt W, Winkler T, Mach M (2009) Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J Gen Virol 90: 1951-1961.
56. Chandler SH, Handsfield HH, McDougall JK (1987) Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J Infect Dis 155: 655-660. (Pubitemid 17052986)
57. Chou SW (1990) Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens. J Infect Dis 162: 738-742.
58. Pignatelli S, Dal Monte P, Rossini G, Chou S, Gojobori T, et al. (2003) Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification of a novel subgroup, geographical distribution and evidence of positive selective pressure. J Gen Virol 84: 647-655. (Pubitemid 36267139)
59. Bale JF Jr., Petheram SJ, Souza IE, Murph JR (1996) Cytomegalovirus reinfection in young children. J Pediatr 128: 347-352. (Pubitemid 26087534)
60. Chandler SH, McDougall JK (1986) Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J Gen Virol 67 (Pt 10): 2179-2192. (Pubitemid 16026798)
61. Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, et al. (2007) Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 40: 1055-1062. (Pubitemid 350142559)